Compare Old Dominion Freight Line Inc (ODFL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs TransMedics Group Inc — how do they compare? Old Dominion Freight Line Inc trades at $180.91 (market cap $37.68B), while TransMedics Group Inc trades at $78.02 (market cap $2.74B). The key difference: Old Dominion Freight Line Inc is far larger — about 13.8× TransMedics Group Inc's market cap, and Old Dominion Freight Line Inc pays a 0.64% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and TransMedics Group Inc for 24 Days on average.
| ODFL | TMDX | |
|---|---|---|
Market Cap | $37.68B | $2.74B |
Volume | 1,550,104 | 949,331 |
Sector | Industrials | Health |
52-Week High | $248.73 | $150.42 |
52-Week Low | $126.29 | $61.99 |
Typical Hold Time | 76 Days | 24 Days |
Enterprise Value | $37.42B | $3.13B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ODFL trades at $175.61, down 1.35% on the day, with a bearish technical signal but strong fundamentals including a 19.44% net income margin and consistent earnings beats. The company recently announced a 4.9% general rate increase effective October 5, 2026, to offset rising costs and support service investments. Despite a high P/E ratio of 34.95, robust profitability and positive cash flow trends underpin the stock's valuation.
The outlook is mixed: analyst consensus is a buy with a $230.93 price target, implying significant upside, but near-term technical pressure and valuation concerns present risks. Key catalysts include execution of the rate increase and Q3 2026 earnings, while macroeconomic pressures on freight demand remain a headwind.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
